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Abstract
Background: Either higher levels of initial DNA damage or lower levels of radiation-induced apoptosis in
peripheral blood lymphocytes have been associated to increased risk for develop late radiation-induced toxicity. It
has been recently published that these two predictive tests are inversely related. The aim of the present study was
to investigate the combined role of both tests in relation to clinical radiation-induced toxicity in a set of breast
cancer patients treated with high dose hyperfractionated radical radiotherapy.
Methods: Peripheral blood lymphocytes were taken from 26 consecutive patients with locally advanced breast
carcinoma treated with high-dose hyperfractioned radical radiotherapy. Acute and late cutaneous and
subcutaneous toxicity was evaluated using the Radiation Therapy Oncology Group morbidity scoring schema. The
mean follow-up of survivors (n = 13) was 197.23 months. Radiosensitivity of lymphocytes was quantified as the
initial number of DNA double-strand breaks induced per Gy and per DNA unit (200 Mbp). Radiation-induced
apoptosis (RIA) at 1, 2 and 8 Gy was measured by flow cytometry using annexin V/propidium iodide.
Results: Mean DSB/Gy/DNA unit obtained was 1.70 ± 0.83 (range 0.63-4.08; median, 1.46). Radiation-induced
apoptosis increased with radiation dose (median 12.36, 17.79 and 24.83 for 1, 2, and 8 Gy respectively). We
observed that those “expected resistant patients” (DSB values lower than 1.78 DSB/Gy per 200 Mbp and RIA values
over 9.58, 14.40 or 24.83 for 1, 2 and 8 Gy respectively) were at low risk of suffer severe subcutaneous late toxicity
(HR 0.223, 95%CI 0.073-0.678, P = 0.008; HR 0.206, 95%CI 0.063-0.677, P = 0.009; HR 0.239, 95%CI 0.062-0.929, P =
0.039, for RIA at 1, 2 and 8 Gy respectively) in multivariate analysis.
Conclusions: A radiation-resistant profile is proposed, where those patients who presented lower levels of initial
DNA damage and higher levels of radiation induced apoptosis were at low risk of suffer severe subcutaneous late
toxicity after clinical treatment at high radiation doses in our series. However, due to the small sample size, other
prospective studies with higher number of patients are needed to validate these results.
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Locally advanced breast cancer (LABC) is a relatively
infrequently tumour which poses a significant clinical
challenge. The management of LABC has evolved
considerably. Initially, patients with LABC were treated
with radical mastectomy [1,2]; thereafter, systemic ther-
apy was subsequently incorporated along with surgery
and radiotherapy (RT) [3]. However, even with such
combined modality therapy, the long-term survival rate
is approximately 50% among patients with LABC [4]. In
cases with inadequate response to neoadjuvant systemic
therapies and inability to perform surgery, RT is the
only possible treatment [5].
Better local control outcomes, with acceptable toxicity,
have been obtained by using high total doses of radia-
tion administered in two small fractions per day (hyper-
fractionation, HF) [6]. HF allows escalation of the
biologically effective dose to the tumour without a sig-
nificant increase in late complications [7]. The radio
therapeutic doses received by the patient are limited by
the tolerance of the normal tissues. Different patients
given a standardized treatment can exhibit a range of
n o r m a la c u t ea n d / o rl a t et i s s u er e a c t i o n s[ 8 , 9 ] .T h u s ,
there is both a dose dependence and a variability in
individual radiosensitivity, where genetic [10,11] and
constitutional factors [9,12] inherit to each patient could
exert an influence.
The prediction of radiation-induced toxicity could help
to select the most appropriate treatment for each patient.
Many predictive factors have been described, including
initial DNA damage [13], cell apoptosis [14], or gene
expression patterns [15,16]. In previous studies, we have
reported an association between the initial number of
DNA double-strand breaks (DSB) induced by x-rays in
peripheral blood lymphocytes (PBL) and radiation-toxicity
[17,18]. Thus, increasing numbers of radiation induced
DSB were related to severe late subcutaneous toxicity in
LABC patients treated with HF [18]. In the other hand,
determination of radiation-induced apoptosis (RIA) in
PBL by flow cytometry analysis has also been proposed as
an approach for predicting normal tissue responses follow-
ing radiotherapy [19,20]. Patients suffering of late toxicity
after RT showed reduced rates of RIA in several tumour
locations [20-22]. Moreover, we have recently reported an
inverse association between the initial DNA damage and
RIA in LABC patients [23].
Taking into account the above background and our
previously observations, we explored the clinical associa-
tion between initial DNA damage and RIA in relation to
radiation-induced toxicity in the set of LABC patients
treated with high dose HF radical RT with long-term
follow-up where this association have been previously
observed [23].
Methods
Characteristics of Patients
Twenty-six consecutive patients diagnosed in our institu-
tion with locally advanced/inflammatory breast cancer
were recruited prospectively for the study after they
signed informed consent to their participation. The study
was approved by the Research and Ethics Committee of
our Institution. All patients were treated between 1992
and 1997; blood samples for radiosensitivity testing were
extracted between February and December 1998. All the
analyses were double-blinded to ensure their reliability.
Mean age of patients was 57.62 ± 12.9 years (range
30-83). The majority of patients were postmenopausal
(69.2%), presented bra size over 100 (65.4%), and
Table 1 Characteristics of patients studied
N (%) Mean ± SD Median
(Range)
Age 57.62 ± 12.9 60 (30-83)
<60 years 12 (46.2)
≥60 years 14 (53.8)
Menopause
Premenopausal 8 (30.8)
Postmenopausal 18 (69.2)
Tumor type
Inflammatory 7 (26.9)
Non-inflammatory 19 (73.1)
Tumor size
T3 1 (3.8)
T4a-T4b 18 (69.2)
T4c-T4d 7 (27.0)
Nodes
N0 18 (69.2)
N1-N2 8 (30.8)
Metastasis
M0 24 (92.3)
M1 2 (7.7)
Bra size 100 ± 10.6 100 (80-120)
<100 9 (34.6)
≥100 17 (65.4)
Systemic treatment
Chemotherapy 4 (15.4)
Hormonal therapy 5 (19.2)
Chemotherapy-hormonal
therapy
17 (65.4)
Received dose (Gy) 78.48 ± 5.7 81.60
(64.8-81.6)
<81.6 7 (26.9)
≥81.6 19 (73.1)
Maximum dose (Gy) 87.36 ± 8.8 89.76
(62.8-101.7)
<89.8 15 (57.7)
≥89.8 11 (42.3)
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patients are detailed in Table 1. Evaluation of clinical toxi-
city was made in each visit. The Radiotherapy Oncology
Group (RTOG) morbidity score system was used to clas-
sify the toxicity of patients. Acute toxicity was evaluated
during and at the end of RT. Late cutaneous and subcuta-
neous toxicity was evaluated every three months during
the first two years, every six months to five years, and
thereafter annually. At the end of the analysis (January
2011), the mean clinical follow-up of survivors (n = 13)
was 197.23 months (range 155-228). The time point finally
used for analysis corresponds to the last evaluation.
Clinical toxicities of patients are detailed in Table 2.
Radiation Treatment
Patients were treated with a dose-escalation radiation ther-
apy schedule using hyperfractionation. All patients
received 60 Gy to the whole breast over a period of 5
weeks in two daily fractions of 1.2 Gy, separated by at least
6 h on 5 days each week. A boost covering the tumour
plus margins was prescribed at a dose of 9.4-21.6 Gy [17].
Peripheral nodes were treated by conventional fractiona-
tion (1.8/2Gy/day) at doses of 50-70 Gy. Supraclavicular
and axillary lymph node areas were treated with an ante-
rior field and a posterior axillary compensating field.
Doses were prescribed to the mid-plane of the axilla and
at a depth of 3 cm in the supraclavicular area. The internal
mammary chain was treated by a direct anterior field with
the dose prescribed at depth of 3 cm. Doses to the breast
ranged from 64.8 Gy to 81.6 Gy (mean 77.5 ± 5.7 Gy;
median 81.6 Gy). Maximum point doses ranged from 62.8
to 101.7 Gy (mean 87.4 ± 8.8; median 89.7 Gy).
Analysis of Initial DNA Damage
Data related to initial DNA damage were obtained from
our files [17]. Shortly, mononuclear cells were isolated
from blood of patients, resuspended in cold DMEM,
and mixed with 1% ultra-low-melting-point agarose to
obtain 250 μl plugs. Irradiation on ice was performed
using a
60Co source (rate dose 1.5 Gy/min, approxi-
mately) as previously reported [17]. Plugs were held 1
hour at 4°C and incubated at 37°C for 24 hours. Initial
radiation-induced DNA damage in PBL was measured
by pulsed-field gel electrophoresis (PFGE) as previously
described [24], and data are summarized in Table 3.
Apoptosis assay and flow cytometry
RIA analyses were performed as previously reported
[21,22]. PBL were irradiated with 0, 1, 2 and 8 Gy. After
irradiation, samples were incubated for 24 hours at 37°C
and 5% CO2. After extraction of cellular pellet, it was
resuspended in 100 μl Annexin V buffer Kit (Pharmin-
gen, Becton Dickinson). After the addition of 4 μlo f
Annexin-V-FITC and 10 μl of propidium iodure (PI),
cells were incubated during 15 minutes at room tem-
perature in the dark. Finally, 400 μl of Annexin V buffer
Kit were added. Every assay was made in triplicate.
The flow cytometry analysis was performed in a
FACScalibur (Becton Dickin s o n ,S a nJ o s é ,C A )u s i n ga
488 nm argon laser, and each sample was analyzed in a
Macintosh Quadra 650 minicomputer (Apple computer
Inc., Cupertino, CA) as previously reported [25]. Data
were analyzed using the CellQuest program (Becton
Dickinson, San José, CA) calculating early and late
apoptosis levels. RIA is defined as the percentage of
total PBL death induced by the radiation dose minus
the spontaneous cell death (control, 0 Gy).
Statistical analyses
Statistical analyses were performed using the SPSS Statis-
tical Package (version 15.0 for Windows). The cut-off
values for continuous variables were the median and the
tertiles of the distribution, as previously reported [17,23].
Univariate and multivariate analyses were performed
using Cox regression. All tests were two sided and statis-
tical significance level was established for a P value less
than 0.05. All samples were processed anonymously.
Results and Discussion
Radiation-induced toxicity in breast cancer patients
The actuarial probability of being free of severe late
cutaneous toxicity, nine-teen years after radiation ther-
apy, was 61.5%, while only 19.2% were free of severe late
Table 2 Number of patients who developed acute/late
toxicity due to radiotherapy
Acute Toxicity Late Toxicity
Grade Cutaneous Cutaneous Subcutaneous
1 6 (23.1) 0 (0.0) 1 (3.8)
2 12 (46.2) 16 (61.5) 5 (19.3)
3 8 (30.8) 10 (38.5) 19 (73.1)
4 0 (0.0) 0 (0.0) 1 (3.8)
Numbers in brackets represent the percentage.
Table 3 Apoptosis data obtained after the irradiation of
PBL at 1, 2 and 8 Gy
Mean ± SD Median (range) Tertiles P
DSB/Gy/DNA unit 1.70 ± 0.83 1.46 (0.63-4.08) 1.28-1.78 0.290
RIA 1Gy 13.33 ± 7.26 12.36 (2.51-29.00) 9.58-15.52 0.971
RIA 2Gy 18.20 ± 7.82 17.79 (4.17-32.08) 14.40-22.43 0.996
RIA 8Gy 29.70 ± 10.05 30.44 (9.02-44.10) 24.83-34.40 0.977
a 13.08 ± 7.21 12.64 (1.64-26.63) 9.91-15.63 0.994
b 7.93 ± 2.68 7.85 (3.18-12.57) 7.14-9.29 0.943
Abbreviations: DSB/Gy/DNA unit = double-strand breaks induced per Gy and
per 200 Mbp; RIA = radiation-induced apoptosis at 1, 2 and 8 Gy after 24
hours. a and b are the constants that define the model. P values were
obtained after a Kolmogorov-Smirnov test.
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10 years after RT [17], 65% of patients were free of
severe late cutaneous toxicity (c
2 test, P =0 . 4 6 3 ) ;w h i l e
29% were free of severe late subcutaneous toxicity (c
2
test, P = 0.031). Severe subcutaneous toxicity is related
to breast shrinkage, fibrosis and sometimes pain. Late
radiation-induced reaction occurs after a latency period
of >90 days (typical range 0.5-5 years). The latency per-
iod in animals is known to be shorter after higher doses,
and in humans, it is even >5 years for moderate doses
or for very late reacting tissues. Late damage progresses
over time, and it is important to highlight that doses
believed safe at 5 years may result in serious late side
effects beyond the 5-year period with any treatment pro-
tocol [26]. For this, the ability to predict late effects in
the treated breast is of great importance, especially
when an unconventional treatment schedule is pre-
scribed. In univariate analysis (simple Cox regression),
severe subcutaneous late toxicity (grades 3-4) was
related to bra size-estimated breast volume (P = 0.037)
(Table 4). Breast size is strongly related to late changes
in breast appearance possible because greater radiation
changes are related to greater dose inhomogeneity in
women with large breasts [12,17,27].
Initial DNA damage levels in breast cancer patients
Initial DNA damage was determined as radiation-
induced double-strand breaks (DSB) in irradiated lym-
phocyte from all 26 LABC patients. There was a wide
variation in DSB among patients (Table 3) with a mean
value of 1.70 ± 0.83 DSB/Gy per 200 Mbp (median,
1.46; range, 0.63-4.08). These results support the sugges-
tion that variation in cell radiosensitivity can be detected
in vitro using radiosensitivity assays on lymphocytes
derived from normal tissues of cancer patients prior to
radiotherapy [18,28-30]. This wide variation in DNA
DSB can be attributed to variation between individuals
more than to variation due to technical or sampling
errors [18,31,32]. Initial DNA damage followed a normal
distribution (Kolmogorov-Smirnov test, P >0 . 0 5 ) ,a n d
data obtained from the present group of patients
matched previously published results for breast cancer
patients [17,18]. However, other molecular events such
as DNA repair foci or DNA-loops should be taken into
account for the correct interpretation of data. It has
been observed that DNA DSB in residual foci and
relaxation of DNA-loops may be linked to induction of
radiation-induced apoptosis in lymphocytes [33-35].
We have previously demonstrated a relation between
the sensitivity of in vitro-irradiated peripheral blood
lymphocytes and the risk of developing late toxic effects
after RT in the present set of patients [17]. However,
the predictive value of initial DNA damage is controver-
sial and different findings have been reported on this
regard. Thus, we agree with some authors [28,30,36]
and we disagree with some others [37]. Moreover, more
initial DSB have been detected in lymphocytes from
normal patients as compared to radiosensitive [38]. In
our opinion, it is important to highlight that the predic-
tive role of initial DNA damage was observed in patients
treated with high-dose of radiation, where the toxicity
reactions are more evident. Differences in the protocol
treatment (RT schedule: dose and type of fractionation)
and in the methodology used (PFGE, comet assay,
gamma-H2AX induction) could help to explain the
discrepancies observed.
Radiation-induced apoptosis in breast cancer patients
Data of RIA were available in all 26 breast cancer
patients as shown in Table 3. RIA increased with radia-
tion dose and data fitted to a semi logarithmic model as
follows: RIA = b ln(Gy) + a. This mathematical model
was defined by two constants: the coefficient in origin a
(determining the spontaneous apoptosis) and the coeffi-
cient b (defining the slope of the curve) [21,22,25,39].
As expected, RIA at 1, 2 and 8 Gy, as well as a and
b constants followed a normal distribution (Kolmo-
gorov-Smirnov test, P > 0.05). There is an important
v a r i a t i o ni nt h eex vivo susceptibility of normal cells
against ionizing radiation. It has been suggested that the
radiation-induced damage measured on lymphocytes
could be proportional to the acute damage evaluated on
the skin of treated patients [40]. Anyhow, it is possible
to estimate the cellular radiosensitivity of PBL of
patients analyzing the RIA rate by annexin V/PI staining
flow cytometric analysis, defining an intrinsic individual
value of radiosensitivity inherit to each patient.
Radiation-induced apoptosis has been proposed as a
reliable method for prediction of normal tissue toxicity
after radiotherapy by us [21,22] and other authors
[14,19,20]. However, some other studies reported no cor-
relations between individual radiosensitivity of cancer
patients and radiation-induced apoptosis in PBLs [41,42].
The lack of uniformity in experimental design helps to
understand these differences. Thus, the cells used in the
assay (total PBL, Epstein-Barr virus-transformed
Table 4 Distribution of patients according to expected
radiation sensitivity after the irradiation of peripheral
blood lymphocytes at 1, 2 and 8 Gy
Expected radiation sensitivity RIA 1 Gy RIA 2 Gy RIA 8 Gy
High (↑ DSB, ↓ RIA) 2 1 3
Intermediate* 13 15 10
Low (↓ DSB, ↑ RIA) 11 10 13
26 26 26
Abbreviations: DSB = DNA double-strand breaks; RIA = radiation-induced
apoptosis.
*Intermediate: patients showing ↑ DSB, ↑ RIA; or ↓ DSB, ↓ RIA.
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radiation protocol, or the analysis strategy are critical to
make possible the comparison among studies.
Association of initial DNA damage and radiation-induced
apoptosis with normal tissue toxicity
As previously published, increasing numbers of radiation
induced DSB were related to severe late toxicity in
breast cancer patients [17]. Thus, among patients receiv-
ing the highest radiation doses (81.6 Gy), those who
showed higher levels of initial DNA damage had a
greater risk of severe subcutaneous toxicity. In the pre-
sent set of patients, no association was observed
between DNA DSB or RIA (at any radiation dose), a or
b constants and normal tissue toxicity, possibly due to
the small sample size (data not shown). An association
between the initial DNA damage and the radiation-
induced apoptosis, as a consequence of x-ray, may exist
[43,44]. DNA DSB are assumed to be the most impor-
tant lesion to induce apoptosis [45]. Depending on the
severity of the DNA damage and the cell type involved,
cells may undergo apoptosis instead of attempting to
repair the damage [46]. Lymphocytes are particularly
sensitive to apoptosis, partly because they induce Bax
expression in response to ionizing radiation exposure
[46]. Lymphocytes from patients who suffered Ataxia-
telangiectasia, Bloom syndrome, or Fanconi anaemia
showed absence of induction of p53 and lower levels of
Bax [47-49]. Apoptosis is initiated following DSB through
an ATM-directed pathway [50]. This could explain the
fact that patients affected by the Ataxia-Telangiectasia
syndrome show the lowest rates of RIA. In that sense, we
have recently reported an inverse association between the
initial DNA damage and RIA in LABC patients [23].
Defective apoptotic response to radiation in PBLs could
help to explain this inverse relation [14].
According to the above observations, high initial DNA
damage [17] or low radiation-induced apoptosis
[14,20-22,25,51] would confer sensitivity to long-term
toxicity, separately. In the present study, we tried to dis-
close the predictive value of both parameters in a com-
bined form. The percentage of patients developing
severe late toxicity determines the maximum acceptable
radiation dose. Generally, an adverse effect frequency of
5%-10% is considered acceptable [52]. We observed that
7.6% (range 3.8-11.5%) of our patients suffered from
severe complications (2, 1, and 3 out of 26 patients ana-
lyzed at 1, 2 and 8 Gy respectively) (Table 4). Because
this subset of patients is too small, we focused on the
expected most resistant patients to RT: those who
presented low initial DNA damage and high radiation-
induced apoptosis (Table 4). Thus, we considered “resis-
tant patients” those who presented DSB values lower
than 1.78 DSB/Gy per 200 Mbp (two lower thirds of the
distribution) and RIA values over 9.58, 14.40 or 24.83
for 1, 2 and 8 Gy respectively (two upper thirds of the
distribution) (Table 3). We did not observe any associa-
tion with late toxicity in the whole series, in univariate
analysis. However, order to the higher received dose
(≥81.6 Gy), we observed that severe subcutaneous late
toxicity (grades 3-4) was related to this radiation-
resistance profile in patients treated with higher dose of
radiation (simple Cox regression, Table 5). Those
patients treated at very high doses (≥81.6 Gy) and who
presented this radiation-resistance pattern were at low
risk of suffer severe subcutaneous late toxicity (Table 5).
Furthermore, in multivariate analysis in the whole series,
severe subcutaneous late toxicity was related to the
received dose (HR 1.138, 95%CI 1.003-1.291, P = 0.045),
the bra size-estimated volume (HR 1.073, 95%CI
1.004-1.147, P = 0.038), and with this radiation-resistant
profile (HR 0.223, 95%CI 0.073-0.678, P = 0.008; HR
0.206, 95%CI 0.063-0.677, P = 0.009; HR 0.239, 95%CI
0.062-0.929, P = 0.039, for RIA at 1, 2 and 8 Gy, respec-
tively) (Table 6). Thus, those patients who presented
lower levels of initial DNA damage and higher levels of
radiation induced apoptosis were at low risk of suffer
severe subcutaneous late toxicity. No relation was found
with acute or late cutaneous toxicity. The close relation
between chromosome fragment production and killing
in many cell systems has been important in linking
DNA DSB to death, because it is a natural step to relate
DNA strand breakage to chromosome breakage.
However, the recognition that apoptosis may be an
important mode of radiation-induced death in some cell
types raise the possibility that other types of damage
may induce apoptosis [13]. A significant association was
Table 5 Univariate analysis for grades 3-4 late
subcutaneous toxicity in the whole series of patients
(n = 26) and in patients who received higher doses
of RT (n = 19)
HR (95% CI) P
Whole series
Age 1.012 (0.975-1.012) 0.535
Received dose 1.079 (0.980-1.189) 0.123
Maximum dose 1.054 (0.991-1.121) 0.096
Bra size 1.056 (1.003-1.111) 0.037
Systemic treatment 1.084 (0.351-3.347) 0.888
Low DSB-High RIA 1Gy 0.564 (0.233-1.370) 0.206
Low DSB-High RIA 2Gy 0.510 (0.204-1.277) 0.150
Low DSB-High RIA 8Gy 0.642 (0.270-1.523) 0.314
Higher dose (≥81.6Gy)
Low DSB-High RIA 1Gy 0.252 (0.077-0.826) 0.023
Low DSB-High RIA 2Gy 0.197 (0.053-0.735) 0.016
Low DSB-High RIA 8Gy 0.240 (0.074-0.778) 0.017
Abbreviations: HR = hazard ratio; CI = confidence interval.
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considered as predictive factors for radiation toxicity,
and normal tissue damage.
Conclusions
Initial DNA double-strand breaks and radiation-
induced apoptosis in peripheral blood lymphocytes
have been proposed as reliable methods for prediction
of radiation-induced late toxicity in normal tissues
[11,17,20]. We have observed, for the first time, a com-
bined role of both parameters. Thus, we propose a
radiation-resistance profile where those patients who
present lower levels of initial DNA damage and higher
levels of radiation induced apoptosis were at low risk
of suffer severe subcutaneous late toxicity in our series.
This finding opens the possibility to develop new pre-
dictor assays taking into account the initial DNA
damage and radiation-induced apoptosis levels, and
introduces new data which may help to understand
and define the complex mechanisms behind the
normal tissue toxicity. Nonetheless, due to the small
sample size, the present results need to be validated in
bigger clinical series.
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